Tailoring Therapy in the Newly Diagnosed Patient With CLL

Slides:

Advertisements

Similar presentations

New Data for Old Drugs in CLL Kanti R. Rai MD Joel Finkelstein Cancer Foundation Professor of Medicine Hofstra North Shore-LIJ School of Medicine Hempstead,

Advertisements

Agne Paner, MD Assistant professor of Medicine RUSH University Medical Center.

Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?

Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Improving Survival in Glioblastoma Multiforme

Post-autologous Transplant Therapy for Hodgkin Lymphoma

Innovations and Issues in Mantle Cell Lymphoma

Relapsed/Refractory Follicular Lymphoma Conundrums

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

Continuing the Advances in Relapsed/Refractory CLL: New Data, New Paradigms.

Current and Future Goals in the Treatment of Relapsed CLL

Goals of Therapy in Relapsed CLL

Program Goals Introduction Case 1: A 44-Year-Old Woman.

Updates in Follicular Lymphoma

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Tailoring Hemophilia Prophylaxis Therapy

Novel and Emerging Approaches to Treating CLL

The Nurse View.

Activity Goals. Activity Goals Case Presentation.

Treatment Decisions in Chemorefractory Follicular Lymphoma

Pharmacist Perspectives on Novel Agents in Multiple Myeloma

Management Challenges in CLL

Updates in Lymphoma From Recent Congresses

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

The Nurse View: Targeted Therapies for the Patient With Metastatic Colorectal Cancer.

Antithrombotic Protection in CAD and HF

Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.

Evaluating Next-Generation BTK Inhibitors

Navigating New Oral Treatment Algorithms in CLL

Targeting BTK Signaling in B-Cell Malignancies

Managing Adverse Events With New Oral Therapies in CLL

Implementing BCR Signaling Inhibitor Therapy in Relapsed CLL

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Optimizing Outcomes and Managing Adverse Events in CLL

Minimal Residual Disease in CLL

Mutational Testing to Select Novel Targeted Therapies in AML

Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.

Personalized Therapy in Relapsed or Refractory CLL

Advancing the Treatment of IBD With Biologics

How to Select Therapy In Newly Diagnosed CLL

Interprofessional Approaches: Managing AEs of Novel Therapies for NHL/CLL.

Myeloid Updates From the Summer Congresses

Battling the Flu: Latest Advances in the Influenza Treatment Arsenal

Cancer-Associated Thrombosis

Non-Chemotherapy Combinations in CLL

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Evaluating BTK Inhibitors in CLL

Individualizing Therapy for Patients With CLL in the Community Practice Setting: Focus on Age and Comorbidities.

Practical Guidance on the Management of Pan-Negative NSCLC

Assessing New Paradigms in CLL: MRD Negativity

Proteasome Inhibitors and Patients

On the Cusp: New Approaches for Multiple Myeloma

What's on the Horizon? Assessing New First-Line Paradigms for AML Patients Ineligible for Intensive Chemotherapy.

Managing CLL With BTK Inhibitors

First-Line FCR: Effect of del(17p) on PFS and OS

CLL - When to treat, how to treat

Patient Stories in PAH: Sequential Therapy in a FC II Patient

Oral Treatment Strategies in CLL

AMD Therapy: Where Are We Now and Where Are We Going?

How to Select Therapy in Relapsed/Refractory CLL

Targeting Apoptosis in AML

MRD Analysis in Chronic Lymphocytic Leukemia

Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL.

Changing Paradigms in Relapsed/Refractory Indolent NHL

Treatment Initiation and Selection in Newly Diagnosed CLL

Utilizing MRD Assessment in Community Practice

Presentation transcript:

Tailoring Therapy in the Newly Diagnosed Patient With CLL

New Therapies/Indications for CLL

Case 1: A 59-Year-Old Man

Case 1 (cont)

FISH Testing in CLL

FCR in Patients With del(17p)

BR as First-Line Therapy

Mechanism of del(17p) in CLL

Novel Agents for Patients With del(17p)

Efficacy of Ibrutinib in 17p

Testing for TP53 Mutations

Ibrutinib: Efficacy by Treatment History

Trial of First-Line Idelalisib

Efficacy of Idelalisib in del(17p)

Safety Concerns With Idelalisib

Phase 2 Trial of Venetoclax in del(17p)

Case 2: A 65-Year-Old Man

CLL10: First-Line FCR vs BR

CLL10: Outcomes Stratified by Age

Phase 3 Intergroup Studies

Case 3: A 79-Year-Old Woman

RESONATE-2: Ibrutinib vs Chlorambucil

CLL11: Study Design

CLL11: Efficacy Outcomes

Infusion Reactions With Obinutuzumab

CLL11: Updated Results

Ongoing Studies of Combinations

Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)